Early detection of pancreatic cancer: Where are we now and where are we going?

Pancreatic cancer (PC) is one of the most lethal malignancies. Recent studies indicate that patients with incidentally diagnosed PC have better prognosis than those with symptoms and that there is a sufficient window for early detection. However, effective early diagnosis remains difficult and depen...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2017-07, Vol.141 (2), p.231-241
Main Authors: Zhou, Bin, Xu, Jian‐Wei, Cheng, Yu‐Gang, Gao, Jing‐Yue, Hu, San‐Yuan, Wang, Lei, Zhan, Han‐Xiang
Format: Article
Language:English
Subjects:
biomarker
Biomarkers
Biopsy
body fluid
Body fluids
Cancer
Diagnostic Imaging
Early Detection of Cancer - methods
early diagnosis
Exosomes
Genetic Predisposition to Disease
Genomics - methods
Humans
liquid biopsy
Medical research
Microbiota
Non-coding RNA
Pancreatic cancer
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - microbiology
Prognosis
Saliva
Sensitivity and Specificity
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer (PC) is one of the most lethal malignancies. Recent studies indicate that patients with incidentally diagnosed PC have better prognosis than those with symptoms and that there is a sufficient window for early detection. However, effective early diagnosis remains difficult and depends mainly on imaging modalities and the development of screening methodologies with highly sensitive and specific biomarkers. This review summarizes recent advances in effective screening for early diagnosis of PC using imaging modalities and novel molecular biomarkers discovered from various “omics” studies including genomics, epigenomics, non‐coding RNA, metabonomics, liquid biopsy (CTC, ctDNA and exosomes) and microbiomes, and their use in body fluids (feces, urine and saliva). Although many biomarkers for early detection of PC have been discovered through various methods, larger scale and rigorous validation is required before their application in the clinic. In addition, more effective and specific biomarkers of PC are urgently needed.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.30670